Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists mimic prostaglandin I2 and bind to the IPR receptor on pulmonary artery smooth muscle cells. This triggers the GS-AC-cAMP-PKA pathway, causing smooth muscle relaxation and vasodilation. This mechanism alleviates symptoms of pulmonary arterial hypertension by reducing pressure in the pulmonary circulation.

Epoprostenol requires continuous intravenous infusion due to its short half-life, demanding constant administration to maintain therapeutic effect. Treprostinil offers greater flexibility, available via continuous intravenous and subcutaneous infusion, inhalation, or oral delivery. This versatility makes treprostinil a more convenient option for many patients.

Beraprost was groundbreaking as the first orally available prostaglandin I2 analog, but clinical trials revealed it showed no significant benefit during long-term use. Despite its convenient oral delivery, its lack of efficacy in sustained treatment led to its discontinuation in favor of more effective alternatives.

Selexipag is an orally active, selective IPR agonist with rapid absorption and a longer half-life than other prostacyclin analogs. Its extended half-life reduces dosing frequency, and oral administration improves patient compliance. These properties make selexipag a practical option for managing pulmonary arterial hypertension.

Iloprost is available exclusively as an inhaled formulation, delivering the drug directly to the pulmonary circulation. This targeted delivery produces potent vasodilation effects on the lung's circulatory system, making it a valuable therapeutic tool for managing pulmonary arterial hypertension patients.

Common adverse effects include musculoskeletal pain, jaw pain, headaches, nausea, abdominal discomfort, diarrhea, flushing, dizziness, systemic hypotension, and cough. These side effects vary in severity among patients. Healthcare providers monitor patients closely to manage adverse effects and adjust treatment as needed.

Epoprostenol remains essential for patients needing potent, continuous therapy due to its rapid onset and strong vasodilatory effects. However, its short half-life necessitates continuous intravenous infusion. Patients unable to tolerate infusion therapy may benefit from treprostinil or selexipag, which offer alternative administration routes.